ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "S08 E03 PI(3)King the Right Target"
Episode Synopsis
Send us a textThe landscape of medication to treat ER+, HER2 negative or low is changing rapidly as patients experience progression on CDK4/6 inhibitors and look for next steps. Now that biomarker testing is more readily available (both tissue and liquid), there are more options particularly in the PI3 kinase pathway. In this episode we will discuss biomarker testing, the PI3 kinase pathway, and an exciting new patient initiative, the PIK3CA Pathbreakers.
More episodes of the podcast Our MBC Life
S11 E02 We Remember
29/10/2025
S11 E01 ASCO 2025: What's New for MBC?
08/10/2025
In God we trust